Winner
Transplant360
Summary of work
The transplant360 programme demonstrates how the pharmaceutical industry can make a valuable contribution to patient health, aside from its product offerings.
Patient focus directed every stage of the programme’s development and implementation, so that the solutions delivered support transplant patients directly and via their HCPs in a 360° approach.
In 2011, the programme targeted adherence to immunosuppressant medication. Non-adherence is complex and was largely unacknowledged by HCPs, despite its catastrophic implications for organ transplant failure. Where non-adherence was recognised, HCPs had felt powerless to address it.
Uptake of the programme across Europe has been impressive, exemplified by 80 per cent of UK transplant units adopting the programme and a more than 10-fold increase in visitors to the transplant360 website.
The programme has also raised the profile of non-adherence as demonstrated by the leading international meeting agenda going from zero mentions of adherence, to widespread coverage between 2010 and 2012. Due to this programme, transplant patients are fully supported in maintaining their health and the health of their new organ.
This highly targeted, patient support programme should become the template that others follow, in terms of its lack of commercial objectives, its patient focus and its powerful engagement of the whole clinical community.
Executive summary as submitted
Judges’ comments
"If you look at the societal value and the patient value of what Astellas is doing, this goes more than the extra mile. It wasn’t about making pharma look better or regenerating an old compound: it was about getting in there an altering the long-term treatment and outcome."
